From: Customer-centric product presentations for monoclonal antibodies
mAb | Administration route and dosing regimena | IV product presentationsa | SC product presentationsa | |
---|---|---|---|---|
IV | SC | |||
Natalizumab | 300 mg q4w | -b | 300 mg/15 mL in single-dose vial | -b |
Alemtuzumab | Initial treatment (2 courses): First course of 12 mg/day on 5 consecutive days; second course of 12 mg/day on 3 consecutive days 12 months after first treatment course Subsequent treatment courses: 12 mg/day on 3 consecutive days as needed, at least 12 months after the previous course | - | 12 mg/1.2 mL in single-dose vial | - |
Ocrelizumab | Start dose: 2*300 mg separated by two weeks Subsequent doses: 600 mg q6m | - | 300 mg/10 mL in single-dose vial | |
Ofatumumab | - | Initial dosing: 20 mg administered at weeks 0, 1, and 2 Subsequent dosing: 20 mg q1m starting at week 4 | - | 20 mg/0.4 mL solution in single-dose prefilled pen or single-dose prefilled syringe |